International Biotechnology Trust plc (IBT) has been highlighted as the top-performing biotech investment trust over the past five years, according to new research published by Kepler Trust Intelligence. The report, produced by Kepler Partners LLP's investment companies team, is described as offering investment bank quality analysis and is available free of charge to UK investors. The publication may draw renewed attention from long-term investors seeking comprehensive, independent-style coverage of the specialist biotechnology sector.

Key Points

  • International Biotechnology Trust plc (IBT) is a closed-ended investment trust focused on the biotechnology sector
  • Kepler Trust Intelligence has published new research designating IBT as the top-performing biotech trust over the past five years
  • The research note is available free to UK investors via trustintelligence.co.uk
  • Investors should note Kepler Partners LLP has disclosed a conflict of interest, acknowledging a commercial relationship with IBT

IBT Identified as Best-Performing Biotech Trust Across Five-Year Period

The central claim of the Kepler Trust Intelligence note is that International Biotechnology Trust has been the top-performing biotech trust over the past five years. The trust operates as a closed-ended investment vehicle with a focus on the biotechnology sector, providing investors with exposure to a specialist area of global healthcare. The research was prepared by Kepler Partners LLP's investment companies team and is characterised in the announcement as designed to serve as a clear and comprehensive reference for long-term investors. No specific performance figures, net asset value data, or portfolio details are disclosed within the announcement itself.

Kepler Partners Discloses Conflict of Interest in IBT Research Note

Kepler Partners LLP has included a prominent disclosure within the announcement stating that the analyst responsible for the report is aware of an existing relationship between Kepler Partners and International Biotechnology Trust, and that this relationship may impair the objectivity of the research. This conflict of interest disclosure is a standard regulatory requirement and is flagged clearly in the note's important information section. Investors reviewing the research should consider this relationship when assessing the independence of the analysis. Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority under FRN 480590.

Free Access to Research Signals Broader Investor Outreach for IBT

The decision to make the Kepler Trust Intelligence note freely available to UK investors, rather than restricting it to institutional or paying subscribers, suggests an intent to broaden awareness of IBT among a wider retail and professional audience. The announcement directs readers to trustintelligence.co.uk for the full note and additional investment trust research. Notably, the research is explicitly stated to be for information purposes only and does not constitute a recommendation to buy, sell, or take any action regarding IBT or any other investment mentioned.